Page 242 - 2022_01-Haematologica-web

C. Pawlyn et al.
Table 1. Baseline characteristics and treatment received for patients within the transplant-eligible pathway and by age group.
Baseline characteristics
Age, median (range), years Sex, n (%)
Male Female
Performance status (World Health Organization), n (%) 0
1
2
≥3
Not available
International Staging System stage, n (%) I
II
III
Not available
Cytogenetic profile#, n (%) Standard risk
High risk
Ultrahigh risk
Treatment within TE pathway
Induction randomisation treatment arm, n (%) CTD
CRD
Patients’ response at end of Induction (+intensification when received), n (%)
Complete response
Very good partial response
Partial response
Minimal response
No change
Progressive disease
Unable to assess
No induction treatment or non- protocol treatment
Death within 60 days of initial randomisation or within 60 of intensification
Not available
Patients who underwent stem cell harvest, n (%) Yes
No Unknown
Reasons stem cell harvest not performed, n (%) Patient decision
Patient not fit/clinicians decision
Disease progression
Death
Allogeneic transplant Other
Median number of CD34+ cells harvested x106/kg (range)
Patients achieving CD34+ stem cell harvest thresholds, n (%)*: ≥ 2x106/kg
≥ 4x106/kg
Patients who received melphalan (% of all patients in age group)
Dose of melphalan administered (% of all patients who received melphalan), n (%)
70 mg/m2
100 mg/m2
140 mg/m2
200 mg/m2 Unknown/other dose
All n=2042
61 (28-75)
1221 (59.8) 821 (40.2)
865 (42.4) 732 (35.8) 257 (12.6) 88 (4.3) 100 (4.9)
611 (29.9) 782 (38.3) 501 (24.5) 148 (7.2)
475 (55.2) 273 (31.7) 112 (13.0)
1021 (50.0) 1021 (50.0)
149 (7.3) 1125 (55.1) 513 (25.1) 60 (2.9) 16 (0.8) 44 (2.2) 23 (1.1) 17 (0.8) 36 (1.8)
59 (2.9)
1423 (69.7) 565 (27.7) 54 (2.6)
129 (22.8) 200 (35.4) 70 (12.4) 58 (10.3) 8 (1.4) 100 (17.7)
4.4 (0.0-90.2)
1277 (93.6) 791 (58.0)
1370 (67.1)
1 (0.1) 14 (1.0) 144 (10.5) 1161 (84.7) 50 (3.6)
<65 n=1396
57 (28-64)
821 (58.8) 575 (41.2)
612 (43.8) 466 (33.4) 182 (13.0) 67 (4.8) 69 (4.9)
440 (31.5) 526 (37.7) 331 (23.7) 99 (7.1)
318 (54.8) 185 (31.9) 77 (13.3)
701 (50.2) 695(49.8)
102 (7.3) 769 (55.1) 355 (25.4) 37 (2.7) 12 (0.9) 30 (2.2) 13 (0.9) 12 (0.9) 22 (1.6)
44 (3.2)
1026 (73.5) 332 (23.8) 38 (2.7)
70 (21.1) 102 (30.7) 52 (15.7) 33 (9.9) 8 (2.4) 67 (20.2)
4.6 (0.0-88.8)
941 (95.0) 628 (63.4)
993 (71.1)
0 (0)
8 (0.8) 55 (5.5) 895 (90.1) 35 (3.5)
Age group 65-69 n=545
67 (65-69)
342 (62.8) 203 (37.2)
205 (37.6) 225 (41.3) 67 (12.3) 20 (3.7) 28 (5.1)
141 (25.9) 219 (40.2) 141 (25.9) 44 (8.1)
129 (55.4) 71 (30.5) 33 (14.2)
273 (50.1) 272 (49.9)
37 (6.8) 297 (54.5) 137 (25.1) 20 (3.7) 4 (0.7) 10 (1.8) 8 (1.5) 5 (0.9) 13 (2.4)
14(2.6)
339 (62.2) 192 (35.2) 14 (2.6)
48 (25.0) 81 (42.2) 13 (6.8) 23 (12.0) 0 (0.0) 27 (14.1)
3.8 (0.0-90.2)
289 (90.0) 146 (45.6)
322 (59.1)
0 (0)
5 (1.6) 64 (19.9) 239 (74.2) 14 (4.3)
70-75 n=101
71 (70-75)
58 (57.4) 43 (42.6)
48 (47.5) 41 (40.6) 8 (7.9) 1 (1.0) 3 (3.0)
30 (29.7) 37 (36.6) 29 (28.7) 5 (5.0)
28 (59.6) 17 (36.2) 2 (4.3)
47 (46.5) 54 (53.5)
10 (9.9) 59 (58.4) 21 (20.8) 3 (3.0)
0 (0.0) 4 (4.0) 2 (2.0) 0 (0.0) 1 (1.0)
1 (1.0)
58 (57.4) 41 (40.6) 2 (2.0)
11 (26.8) 17 (41.5) 5 (12.2) 2 (4.9) 0 (0.0) 6 (14.6)
3.1 (0.0-7.7)
47 (88.7) 17 (32.1)
55 (54.5)
1 (1.8)
1 (1.8) 25 (45.5) 27 (49.1) 1 (1.8)
continued on following page
234
haematologica | 2022; 107(1)